# A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

> **NCT00774345** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 317 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00774345
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-27
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774345, "A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00774345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*